Prospective randomized controlled study on bestatin in resectable gastric cancer--third report.
The efficacy of Bestatin as adjuvant immunochemotherapy for patients with resectable gastric cancer was investigated. Ninety-six patients with similar background factors were randomized into two groups; a control group and an experimental group, the patients in the experimental group receiving a daily oral dose of 60 mg Bestatin over a long period. All 96 patients were treated with a bolus intravenous injection of mitomycin C (MMC) plus oral administration of tegafur (FT-207, FT). The survival rate of the patients in the MMC + FT + Bestatin group was more favorable than that of the patients in the MMC + FT group, but the difference was not statistically significant. The survival rates of the MMC + FT + Bestatin group patients in the stratification of stage III + IV and positive histological serosal invasion, ps(+), were significantly superior to those of the MMC + FT group patients (Logrank test: p less than 0.05). Moreover, in patients with positive histological serosal invasion, the recurrence of peritoneal dissemination was significantly suppressed in the MMC + FT + Bestatin group.
Niimoto
M
M
Department of Surgery, Hiroshima University, Japan.
Saeki
T
T
Toi
M
M
Nishiyama
M
M
Hirai
T
T
Yanagawa
E
E
Hattori
T
T
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000626:Aminopeptidases / Q000037:antagonists & inhibitors*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005743:Gastrectomy; D006801:Humans; D007930:Leucine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008213:Lymphocyte Activation; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014374:Tuberculin Test
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D000626:Aminopeptidases; D007930:Leucine; C012211:ubenimex